

RESPONSE UNDER 37 C.F.R. 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1636

151

Zeta

PATENT 4-9-01

S/N 09/454,737

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	PERRICAUDET ET AL.	Examiner:	D. GUZO
Serial No.:	09/454,737	Group Art Unit:	1636
Filed:	DECEMBER 6, 1999	Docket No.:	8076.85USC1
Title:	VIRAL RECOMBINANT VECTORS FOR EXPRESSION IN MUSCLE CELLS		

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on January 11, 2001.

By:

Name:

Kristine A. Wachter
Kristine A. Wachter

RESPONSE AND AMENDMENT
pursuant to 37 C.F.R. § 1.116

BOX AF
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In complete response to the Official Action mailed October 11, 2000, kindly amend the above-captioned application as follows:

In the Claims

Please delete claims 20 and 21 without prejudice or disclaimer of the subject matter contained therein.

Please amend Claim 15 as follows:

15. (Twice Amended) A composition comprising (i) a non replicative recombinant adenoviral vector wherein said non replicative recombinant adenoviral vector comprises a heterologous polynucleotide sequence encoding a polypeptide, which polynucleotide sequence is inserted into [an ntirely] a deleted E1 region of said non replicative recombinant adenoviral